Levels of F2 isoprostane in Behcet's disease: Correlation with cardiometabolic risk factors

dc.authorid0000-0002-1483-997X
dc.authorid0000-0002-1524-2809
dc.contributor.authorSagun, Gul
dc.contributor.authorOğuz, Aytekin
dc.contributor.authorMesci, Banu
dc.contributor.authorIsbilen, Banu
dc.contributor.authorKavala, Mukaddes
dc.contributor.authorKeskin, Havva
dc.contributor.authorTakır, Mümtaz
dc.date.accessioned2025-05-10T19:34:10Z
dc.date.issued2015
dc.departmentİstanbul Medeniyet Üniversitesi
dc.description.abstractObjective: Behcet's disease (BD) is a chronic inflammatory disease and recent findings suggest a role of oxidative stress in the pathogenesis of BD. Free radical-induced oxidative stress is also involved in the pathogenesis of cardiovascular and other rheumatic diseases. Oxidative stress may be detected in vivo by measuring F-2 isoprostanes. Here, we measured plasma levels of F-2 isoprostane in patients with BD and evaluated the correlation of F-2 isoprostane with cardiometabolic risk factors. Methods: Forty-three patients with BD in remission and 37 age-and sex-matched controls were recruited for the study. Blood samples were obtained to determine F-2 isoprostane, C-reactive protein levels, erythrocyte sedimentation rate, and other biochemical parameters. Homeostasis model assessment insulin resistance and body mass index were calculated. Systolic blood pressure, diastolic blood pressure, and waist circumference were measured. Results: Plasma F-2 isoprostane, fasting plasma glucose, triglyceride, and C-reactive protein levels were significantly higher in patients with BD compared with healthy controls, whereas high-density lipoprotein cholesterol levels were significantly lower in patients with BD. F-2 isoprostane levels did not correlate with cardiometabolic risk factors, C-reactive protein levels, or erythrocyte sedimentation rate. Conclusion: High levels of F-2 isoprostane in patients with BD indicate oxidative stress. Antioxidant therapeutic approaches could potentially affect the course of this disease.
dc.identifier.doi10.1179/1351000215Y.0000000008
dc.identifier.endpage227
dc.identifier.issn1351-0002
dc.identifier.issue5
dc.identifier.pmid25867971
dc.identifier.scopus2-s2.0-84940052884
dc.identifier.scopusqualityQ2
dc.identifier.startpage223
dc.identifier.urihttps://doi.org/10.1179/1351000215Y.0000000008
dc.identifier.urihttps://hdl.handle.net/20.500.14730/8425
dc.identifier.volume20
dc.identifier.wosWOS:000360024800005
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherManey Publishing
dc.relation.ispartofRedox Report
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20250302
dc.subjectBehcet's disease
dc.subjectF-2 isoprostane
dc.subjectCardiometabolic risk factors
dc.titleLevels of F2 isoprostane in Behcet's disease: Correlation with cardiometabolic risk factors
dc.typeArticle

Dosyalar

Orijinal paket

Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
8425.pdf
Boyut:
157.49 KB
Biçim:
Adobe Portable Document Format